Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH21 + Osimertinib in EGFR-mutated NSCLC
NCT06306456Phase 2Recruiting
- Sponsor
- Genhouse Bio
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GH21 in non-small cell lung cancer (NSCLC), sponsored by Genhouse Bio. Primary endpoints: Number of Participants with Dose Limiting Toxicities at 2 years, Number of Participants with Adverse Events at 2 years and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
GH21
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06306456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06306456.